The novel coronavirus pandemic has upended our lives, creating a far-from-normal “new normal.” And it has also given rise to countless collaborations between and among universities, hospitals, medical centers, pharma companies and others to pool their talent and resources to discover, test, manufacture and distribute diagnostics, treatments, vaccines, personal protective equipment and other resources needed to fight the pandemic. Antitrust law poses no risk to these collaborations, so long as they remain focused on their core missions. But at the same time, antitrust law recognizes that in cooperating and exchanging information and insights for those missions there is the potential for “spill-over effects” that can create antitrust risk. The trick is to know where that dividing line is and to avoid crossing over it.
- Perryman PTAB Study for Unified Patents Leaves Out Half of the Story
- Patents are from Mars, Trade Secrets are From Venus
- The Rise of Australia’s Small Boutique Patent and Trademark Firms
- Tech Companies Should Strongly Consider Monetizing Their Patent Portfolios During the Economic Downturn
- (Not) Copyright Infringement: Is dbrand Infringing Nintendo’s IP?
- Other Barks & Bites for Friday, August 7: USPTO Increases Fees for Patent Filings and AIA Trials, State AGs Ask HHS to March-In on Remdesivir, CAFC Denies American Axle Rehearing
- No, You Can’t March in On Remdesivir
- Google v. Oracle Perspective: Google’s Android ‘Cheat Code’ was to Copy Oracle’s Code
- Illumina v. Ariosa: En Banc Rehearing Denied, Illumina Patents Again Upheld on Rehearing
- CAFC Evenly Splits on En Banc Rehearing of American Axle’s Driveshaft Patent